TY - JOUR
T1 - Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes
T2 - A meta-analysis update
AU - Salah, Husam M.
AU - Al'Aref, Subhi J.
AU - Khan, Muhammad Shahzeb
AU - Al-Hawwas, Malek
AU - Vallurupalli, Srikanth
AU - Mehta, Jawahar L.
AU - Mounsey, J. Paul
AU - Greene, Stephen J.
AU - McGuire, Darren K.
AU - Lopes, Renato D.
AU - Fudim, Marat
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/3
Y1 - 2021/3
N2 - In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
AB - In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
UR - http://www.scopus.com/inward/record.url?scp=85099472749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099472749&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2020.12.007
DO - 10.1016/j.ahj.2020.12.007
M3 - Letter
C2 - 33385359
AN - SCOPUS:85099472749
SN - 0002-8703
VL - 233
SP - 86
EP - 91
JO - American heart journal
JF - American heart journal
ER -